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Abstract
Antibody protection against flaviviruses is associated with the development of neutralizing antibodies against the viral
envelope (E) protein. Prior studies with West Nile virus (WNV) identified therapeutic mouse and human monoclonal
antibodies (MAbs) that recognized epitopes on domain III (DIII) of the E protein. To identify an analogous panel of
neutralizing antibodies against DENV type-1 (DENV-1), we immunized mice with a genotype 2 strain of DENV-1 virus and
generated 79 new MAbs, 16 of which strongly inhibited infection by the homologous virus and localized to DIII. Surprisingly,
only two MAbs, DENV1-E105 and DENV1-E106, retained strong binding and neutralizing activity against all five DENV-1
genotypes. In an immunocompromised mouse model of infection, DENV1-E105 and DENV1-E106 exhibited therapeutic
activity even when administered as a single dose four days after inoculation with a heterologous genotype 4 strain of DENV1. Using epitope mapping and X-ray crystallographic analyses, we localized the neutralizing determinants for the strongly
inhibitory MAbs to distinct regions on DIII. Interestingly, sequence variation in DIII alone failed to explain disparities in
neutralizing potential of MAbs among different genotypes. Overall, our experiments define a complex structural epitope on
DIII of DENV-1 that can be recognized by protective antibodies with therapeutic potential.
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DENV is an enveloped virus with a single-stranded, positivesense RNA genome [6]. The 10.7 kilobase genome is translated as
a single polyprotein, which is cleaved into three structural proteins
(C, prM/M, E) and seven nonstructural (NS) proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, NS5). The mature DENV
virion has a well-organized outer protein shell, a lipid membrane
bilayer, and a less-defined inner nucleocapsid core [7,8]. The
ectodomains of DENV E proteins are assembled as dimers with
each subunit comprised of three discrete domains [9–11]. Domain
I (DI) is a central, eight-stranded b-barrel, which contains a single
N-linked glycosylation site in most DENV strains. Domain II (DII)
is a long, finger-like protrusion from DI and contains a second
N-linked glycan that binds to DC-SIGN [12–15] and the highly
conserved fusion peptide at its distal end. Domain III (DIII), which
adopts an immunoglobulin-like fold, has been argued to contain
a cell surface receptor recognition site [16–19]. Exposure to mildly
acidic conditions in the trans-Golgi secretory pathway promotes virus maturation through a structural rearrangement of

Introduction
Dengue virus (DENV) is a member of the Flaviviridae family and is
related to the viruses that cause yellow fever, and the Japanese, St.
Louis, and the West Nile encephalitides [1]. DENV infection after
mosquito inoculation causes a spectrum of clinical disease ranging
from a self-limited febrile illness (DF) to a life threatening
hemorrhagic and capillary leak syndrome (Dengue Hemorrhagic
Fever (DHF)/Dengue Shock Syndrome (DSS)). Globally, there is
significant diversity among DENV strains, including four distinct
serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) that differ at
the amino acid level in the viral envelope proteins by 25 to 40 percent.
There is additional complexity within a given DENV serotype, as
genotypes vary further by up to ,6% and 3% at the nucleotide and
amino acid levels, respectively [2,3]. At present, no approved antiviral
treatment or vaccine is available, and therapy is supportive. DENV
causes an estimated 25 to 100 million infections and 250,000 cases of
DHF/DSS per year worldwide, with 2.5 billion people at risk [4,5].
PLoS Pathogens | www.plospathogens.org
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which neutralized all genotypes, were therapeutically active even
when administered as a single dose four days after infection. These
studies define the complexity of epitopes on DIII of DENV-1 that
is recognized by highly protective antibodies with therapeutic
potential.

Author Summary
Dengue virus (DENV) is a mosquito-transmitted virus that
infects 25 to 100 million humans annually and can progress
to a life-threatening hemorrhagic fever and shock syndrome. Currently, no vaccines or specific therapies are
available. Prior studies identified a highly neutralizing
monoclonal antibody (MAb) against West Nile virus, a
related flavivirus, as a candidate therapy for humans. In this
study, we generated 79 new MAbs against the DENV type 1
(DENV-1) serotype, 16 of which strongly inhibited infection
in cell culture. Using structural and molecular approaches,
the binding sites of these inhibitory MAbs were localized to
distinct regions on domain III of the DENV-1 envelope
protein. We tested the protective capacity of all of the
neutralizing MAbs in mice against infection by a strain of
DENV-1 from a distinct genotype. Only two of the MAbs,
DENV1-E105 and DENV1-E106, showed efficacy in a postexposure treatment model, and these antibodies efficiently
neutralized all five DENV-1 genotypes. Collectively, our
studies define a complex structural binding site on domain
III of the envelope protein for MAbs with therapeutic
potential against DENV-1.

Results
MAb generation
Previous studies with WNV and DENV-2 demonstrated that
MAbs against DIII of the E protein protect against infection of cells
[26,27,29,32,35,41] and, in the case of WNV, in animals [29]. To
date, few DENV-1 MAbs have been characterized functionally or
mapped structurally. To develop neutralizing MAbs, mice were
infected with the 16007 (genotype 2) prototype strain of DENV-1
and in some cases, boosted with recombinant DIII from the
homologous DENV-1 strain. Initial immunization studies were
performed with wild type BALB/c mice as done previously with
WNV [29]. Because low neutralizing titers (,1/100) were achieved,
likely because of poor replication of DENV-1, we switched to an
immunodeficient (IFN-abR2/2) strain in the C57BL/6 background. After screening more than 3,000 hybridoma clones as part
of five independent fusions, we isolated and cloned 79 new MAbs
that recognized cells infected with DENV-1 (Table S1).
All MAbs were initially tested semi-quantitatively for neutralization of the homologous DENV-1 strain by a single endpoint
plaque reduction assay in Vero or BHK21-15 cells using neat
hybridoma supernatant (,10 mg/ml). Of the MAbs generated, 18
showed no inhibitory activity (,15% neutralization), 45 had
modest inhibitory activity (15–75% neutralization) and 16 were
strongly inhibitory (.95% neutralizing). All MAbs were screened
for E protein domain recognition using yeast that expressed
DENV-1 DI-II or DIII on their surface (Table S1): 14 bound to
yeast expressing DI-DII, 53 recognized DIII, and the remaining
12 did not bind either DI-DII or DIII, indicating they recognized
epitopes that are not present on the truncated yeast-expressed
forms of DENV-1 E protein. All MAbs were tested for crossreactivity using cells infected with different serotypes of DENV or
WNV. Five of the fourteen DI-DII-specific MAbs and 26 of the 53
DIII-specific MAbs cross-reacted with other serotypes of DENV.
Only 3 of the 78 MAbs bound all DENV serotypes and WNV.
One of the neutralizing MAbs, DENV1-E50, was of the IgM
isotype and not evaluated further here.

the flavivirus E proteins and cleavage of prM to M by a furin-like
protease [20,21]. Mature DENV virions are covered by 90 antiparallel E protein homodimers, which are arranged flat along the
surface with quasi-icosahedral symmetry.
Many flavivirus neutralizing antibodies recognize the structural
E protein (reviewed in [22]). Serotype-specific MAbs against
DENV reportedly have the greatest neutralizing activity [23,24]
although some sub-complex specific MAbs, which recognize some
but not all DENV serotypes, also are inhibitory [25–27].
Protection in animals by antibodies correlates generally with the
degree of neutralizing activity in vitro [24,28–31]. Several typespecific strongly neutralizing antibodies against individual flaviviruses (e.g., West Nile virus (WNV), Japanese encephalitis virus
(JEV), DENV-2, DENV-4, and yellow fever virus (YFV)) have
been localized to epitopes in DI and DIII [26,29,32–42]. Based on
their potency of neutralization and protection in vivo, anti-WNV
humanized or human MAbs are in clinical development as
candidate therapeutics (reviewed in [43]). Although type-specific
neutralizing MAbs against DENV-1 have been characterized
[44,45], few have been mapped to specific amino acids or
structural determinants. To date, only two neutralizing IgM
against DENV-1 were mapped by neutralization escape selection
to amino acids E279 and E293, which lie outside of DIII [46].
To develop neutralizing MAbs against DENV-1 with possible
clinical potential, mice were infected with a genotype 2 strain of a
DENV-1 virus, and boosted with recombinant protein of the
homologous virus. 79 new MAbs against DENV-1 were generated:
15 of these were DIII-specific IgG and strongly neutralized the
homologous DENV-1 strain. Of these, 9 were serotype-specific, 5
were sub-complex-specific, and only 1 MAb cross-reacted with all
4 serotypes of DENV. Several MAbs failed to neutralize at least
one DENV-1 strain of a distinct genotype, suggesting that
antibody recognition of the neutralizing epitopes on DIII varied
among genotypes.
As a first step towards generating antibody therapeutics against
DENV-1, we evaluated the protective capacity of these MAbs in an
immunocompromised IFN-abR2/2 6IFN-cR2/2 (AG129) mouse
infection model with a heterologous DENV-1 genotype 4 strain.
Among the strongly neutralizing antibodies tested, only four were
highly protective. Two MAbs, DENV1-E105 and DENV1-E106,
PLoS Pathogens | www.plospathogens.org

Characterization of strongly neutralizing MAbs against
DENV-1
Studies with neutralizing mouse MAbs against DENV-2 defined
a type-specific epitope on the lateral ridge of DIII (DIII-LR) and
an adjacent more conserved b-strand termed the sub-complexspecific DIII A-strand epitope [25–27,41]. As our single endpoint
titer neutralization experiments showed that all 15 inhibitory IgG
MAbs localized to DIII of DENV-1, we analyzed their reactivity
patterns with other strains. We found that 9 of the 15 neutralizing
IgG MAbs were serotype-specific and showed no cross-reactivity
to DENV-2, DENV-3, DENV-4 or WNV-infected cells. Five
MAbs were sub-complex specific and bound some but not all
DENV serotypes. Only one MAb, DENV1-E102, cross-reacted
with all DENV serotypes but not with WNV-infected cells
(Table 1).

Genotype-specific reactivity of anti-DENV-1 MAbs
As variation exists in the genetic composition of viruses within a
given DENV serotype, an intra-serotype genotype classification
system was developed [2,3], with a given genotype of a serotype
2
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Table 1. Binding of MAbs to cells infected with other DENV serotypes.

MAb

Neutralization

Binding to virus-infected cellsa

Specificity

b

DENV-1

DENV-2

DENV-3

DENV-4

16007

16681

16652

H241

DENV1-E90

Strong

Sub-complex

+++

2

2

+++

DENV1-E95

Strong

Type

+++

2

2

2

DENV1-E98

Strong

Sub-complex

+++

+

+++

2

DENV1-E99

Strong

Sub-complex

+++

+++

2

2

DENV1-E100

Strong

Type

+++

2

2

2

DENV1-E101

Strong

Type

+++

2

2

2

DENV1-E102

Strong

Cross-reactive

+++

+++

+

+++

DENV1-E103

Strong

Type

+++

2

2

2
2

DENV1-E104

Moderate

Type

+++

2

2

DENV1-E105

Strong

Type

+++

2

2

2

DENV1-E106

Strong

Sub-complex

+++

2

2

+++

DENV1-E108

Strong

Type

+++

2

2

2

DENV1-E111

Strong

Type

+++

2

2

2

DENV1-E112

Strong

Type

+++

2

2

2

DENV1-E113

Strong

Sub-complex

+++

+++

2

+++

Raji-DC-SIGN-R cells were infected with the indicated DENV serotypes and relative binding was determined by flow cytometry based on the mean fluorescence intensity
after staining with MAbs.
a
+++, strong binding (40–100%) to infected cells; +, weak binding (15–40%) to infected cells; 2, no appreciable binding detected.
b
sub-complex MAbs recognize some but not all DENV serotypes.
doi:10.1371/journal.ppat.1000823.t001

DENV1-E106) showing 100% neutralization of all genotypes.
Several MAbs showed reduced neutralizing potential for individual
genotypes even at the relatively high (,10 mg/ml) concentration of
MAb used in the assay. For example, 9, 12, 12, and 14 MAbs
neutralized infection by DENV genotypes 1, 3, 4, and 5,
respectively. This was especially surprising for the genotype 1
strain as no appreciable reduction in binding to infected cells was
observed (Table 2). As an example, DENV1-E104 showed
relatively normal binding to the genotype 1 strain yet showed a
92% loss in neutralization activity. Some MAbs (DENV1-E100 and
DENV1-E111), which had decreased binding to genotype 3
infected cells, also showed reduced inhibitory activity. Others
(e.g., DENV1-E104) sustained normal inhibitory activity despite
attenuated binding to fixed, permeabilized cells. Although more
studies are necessary, this could reflect an epitope that is more
sensitive to fixation in the context of recognition of specific
genotypes.
To more rigorously characterize the neutralizing potency, we
purified MAbs and assessed their inhibitory activity against the
homologous genotype 2 (16007) strain in cell culture by
performing a dose-response curve and determining the concentration of MAb (PRNT50, expressed here as ng/ml of antibody)
that blocked plaque formation by 50% (Table 4). For the
homologous genotype 2 16007 strain, 8 of 15 MAbs potently
neutralized infection with PRNT50 values below 5 ng/ml. This
value is significant as it is lower than that observed with our most
inhibitory anti-WNV MAb (E16), which functions successfully as a
post-exposure therapeutic agent [29,49,50]. Six other MAbs also
showed strong inhibitory activity with PRNT50 values against
16007 of between 10 and 70 ng/ml. Only one MAb, E104 showed
modest activity with a PRNT50 value of ,600 ng/ml.
Given our findings of genotype variation with respect to single
endpoint neutralization using hybridoma supernatants, we repeat-

having no more than 6% nucleotide sequence divergence in the E
gene [47]. To address whether the neutralizing MAbs were
affected by the variation within the serotype, we tested reactivity
and neutralizing potential against individual strains that encompass the five distinct DENV-1 genotypes: Asian genotype 1 (strain
TVP-2130), Thai genotype 2 (strain 16007), Malaysian genotype 3
(TVP-5175), South Pacific genotype 4 (strain West-Pac 74), and
American/African genotype 5 (strain 3146 SL).
(a) Binding to different DENV-1 genotypes. To determine
whether antibodies recognized different genotypes of DENV-1,
we infected Raji-DC-SIGN-R or C6/36 cells (depending on
permissiveness) with strains of the five different genotypes of
DENV-1. Infected cells were incubated with hybridoma supernatants and analyzed by flow cytometry. All neutralizing MAbs
tested efficiently recognized genotypes 1, 2, 4, and 5. However, a
few of the MAbs (DENV1-E100, DENV1-E104, and DENV1E111) showed reduced binding to cells infected with the genotype
3 strain (Table 2). In contrast, other DIII-specific nonneutralizing MAbs (e.g., DENV1-E91) showed reduced binding
to several of the heterologous DENV-1 genotypes (Fig 1).
(b) Neutralizing potential of MAbs against different DENV1 genotypes. Although most MAbs retained binding to cells

infected with many of the genotypes, we questioned whether this
translated into efficient cross-genotypic neutralization. A recent
study of neutralization escape mutants with human MAbs against
WNV showed that retention of binding did not necessarily sustain
neutralizing activity [48]. To evaluate this, we assessed semiquantitatively the inhibitory activity of hybridoma supernatants of
15 neutralizing MAbs against all five genotypes by a standard
plaque reduction assay with 102 PFU of virus in Vero or BHK21-15
cells, depending on the strain (Table 3). Only 8 of 15 hybridoma
supernatants neutralized strains from all five genotypes by greater
than 90%, with three MAbs (DENV1-E103, DENV1-E105, and
PLoS Pathogens | www.plospathogens.org
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Table 2. MAb binding to cells infected with different genotypes of DENV-1 virus.
Binding to virusa

MAb

Genotype 1

Genotype 2

Genotype 3

Genotype 4

Genotype 5

TVP-2130

16007

TVP-5175

West Pac-74

3146-SL

DENV1-E90

93

98

83

95

95

DENV1-E95

94

98

81

95

95

DENV1-E98

97

98

83

96

97

DENV1-E99

96

98

84

96

97

DENV1-E100

93

98

70

94

95

DENV1-E101

93

98

82

95

96

DENV1-E102

92

98

78

94

94

DENV1-E103

94

98

83

95

95

DENV1-E104

93

98

71

94

92

DENV1-E105

89

98

75

94

95

DENV1-E106

94

98

75

95

95

DENV1-E108

93

98

77

95

94

DENV1-E111

90

98

57

93

92

DENV1-E112

94

98

81

95

95

DENV1-E113

90

98

74

93

93

a

Depending on the strain, Raji-DC-SIGN-R or C6/36 cells were infected with different genotypes of DENV-1 viruses. Fixed and permeabilized infected cells were
incubated with the indicated MAbs (10 mg/ml) to determine the binding efficiency by flow cytometry. The data shown are the mean percentage of positive cells and
derived from three independent experiments. Values underlined and italicized are statistically different (P,0.05).
doi:10.1371/journal.ppat.1000823.t002

DENV-1 MAbs was significantly altered against strains of a
different DENV-1 genotype.

ed the dose-response curve analysis with a heterologous genotype 4
(West Pac-74) (Table 4). Surprisingly, the neutralizing activity was
markedly decreased for all MAbs against the heterologous DENV1 genotype (e.g., 6 to 9600-fold for DENV1-E100 and DENV1E113, respectively). Only 2 MAbs, DENV1-E105 and DENV1E106, retained strong neutralizing activity (#20 ng/ml) against
the West Pac-74 strain. Seven of 15 MAbs neutralized West-Pac
74 poorly with PRNT50 values greater than 1 mg/ml of antibody.
Thus, the neutralizing efficiency of several DIII-specific anti-

Crystal structure of DENV-1 DIII and analysis of genotypic
variation
To begin to understand the disparity in inhibitory potential of
the DIII-specific neutralizing MAbs among different genotypes,
we determined the X-ray crystal structure of recombinant DIII of
the 16007 (genotype 2) strain at 2.25-Å resolution (Fig 2 and

Figure 1. Binding of MAbs to cells infected with different genotypes of DENV-1. C6/36 insect cells were infected with strains of DENV-1
virus corresponding to all five genotypes. After fixation and permeabilization, MAbs were incubated with infected cells and binding was assessed by
flow cytometry. The data shown are representative histograms from two independent experiments with a neutralizing (DENV1-E106, upper panels)
and non-neutralizing (DENV1-E91, lower panels) MAb.
doi:10.1371/journal.ppat.1000823.g001

PLoS Pathogens | www.plospathogens.org

4

April 2010 | Volume 6 | Issue 4 | e1000823

Therapeutic MAb Neutralization of DENV-1

Table 3. MAb neutralization of different DENV-1 genotypes.
a

MAb

Percent Neutralization (%)

Genotype 1

Genotype 2

Genotype 3

Genotype 4

Genotype 5

TVP-2130

16007

TVP-5175

West Pac-74

3146-SL

DENV1-E90

95

100

93

97

100

DENV1-E95

93

100

94

72

93

DENV1-E98

90

100

100

99

100

DENV1-E99

95

100

97

96

100

DENV1-E100

100

100

96

97

99

DENV1-E101

98

100

100

92

100

DENV1-E102

79

100

100

98

100

DENV1-E103

100

100

100

100

100

DENV1-E104

8

96

51

55

48

DENV1-E105

100

100

100

100

100

DENV1-E106

100

100

100

100

100

DENV1-E108

69

100

86

97

95

DENV1-E111

15

100

63

85

91

DENV1-E112

46

100

76

79

94

DENV1-E113

71

100

97

92

100

a

Neutralizing activity was determined semi-quantitatively by single endpoint plaque reduction assay on BHK21 or Vero cells with neat hybridoma supernatant cells and
102 PFU of the indicated DENV-1 genotype. The data was derived from at least two independent assays performed in duplicate. Highlighted, italicized values indicate a
genotypic specific reduction in neutralizing potential of a given MAb using neat hybridoma supernatant of greater than 20%.
doi:10.1371/journal.ppat.1000823.t003

Table S2). Among the DENV-1 strains that represent the five
different genotypes used in this study, variation in DIII was limited
to nine residues, six of which were conservative substitutions (Fig 2
and Fig 3B). Four of the conservative substitutions (V/I380,
L/V351, T/S339, and D/N341) are predicted to be partially or
completely solvent inaccessible in the isolated DENV-1 DIII
crystal structure and cryoelectron microscopy reconstruction of the
mature virion [51], and thus, should not directly affect antibody
engagement. In contrast, the conservative substitution K/R361
should be accessible due to its location in the DE loop. S/T397,
the remaining conservative substitution is located after the
G-strand in a region that links DIII with the first a-helix of the
stem anchor motif. Of the three non-conservative substitutions,
A/T369 is completely buried and although A/I/V345 is largely
solvent accessible in the DIII crystal structure, it is likely buried in
the virion according to cryoelectron microscopy reconstructions.
The remaining non-conservative substitution (M/V297) occurs in
the N-terminal linker region that connects to DI, which is solvent
accessible in the DIII crystal structure, but less so in the mature
virion structure. In summary, amino acid variation in DIII among
the five different DENV-1 genotypes is modest, with the majority
of changes being solvent inaccessible. Indeed, none of the observed
genotypic variation occurs in residues previously implicated as
critical to the creation of neutralizing antibody epitopes in DENV
or related flaviviruses.

Table 4. PRNT50 values of MAbs against a homologous and
heterologous DENV-1 strain.

MAb

Genotype 2

Genotype 4

16007

West Pac-74

PRNT50
(ng/ml) 6 SD

PRNT50
(ng/ml) 6 SD

Fold reduction
(WP 74/16007)

DENV1-E90

1.961.9

11616241

611

DENV1-E95

1463.1

856164480

612

DENV1-E98

1362.5

7576212

58

DENV1-E99

1163.9

8036116

73

DENV1-E100

2465.0

145642

6

DENV1-E101

0.860.5

10296327

1286

DENV1-E102

1.160.4

5756546

522

DENV1-E103

0.760.3

5426192

774

DENV1-E104

5906105

2306862720

39

DENV1-E105

0.560.09

2069.7

40

DENV1-E106

0.660.3

1367.5

21

DENV1-E108

7069.1

391261930

56

DENV1-E111

3.761.6

1519864905

4107

DENV1-E112

42613

1889163331

450

DENV1-E113

1.360.3

1249868911

9614

Epitope mapping of DIII neutralizing MAbs
On the basis of studies that mapped DIII-specific MAbs against
WNV and DENV-2 [25–27,29,41], we initially used reverse
genetics to engineer corresponding mutations (S305P, K307E,
E309K, K310E, V324I, T329G, D330G, K361E, E362K,
E384K, K385E, and K393E) on residues of the BC, DE, and
FG loops and the A b-strand (A-strand) of DIII of the genotype 2

Neutralizing activity was determined by plaque reduction assay on BHK21 with
increasing concentrations of purified MAb cells and 102 PFU of the indicated DENV-1
genotype. The data was derived from three independent experiments performed in
duplicate. PRNT50 values were calculated by non-linear regression analysis and SD
indicates the standard deviations. The column on the right was obtained by dividing
the PRNT50 values from West Pac-74 by those of 16007 for a given MAb.
doi:10.1371/journal.ppat.1000823.t004
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The two most protective MAbs in vivo (see below), DENV1E105 (type-specific) and DENV1-E106 (sub-complex specific), lost
binding when residues on the BC (G328, T329 and D330), DE
(K361E and E362K), and FG (K385) loops of the DIII-LR region
were altered. Similarly, other protective MAbs (DENV1-E100
and DENV1-E103) also lost binding when residues in the BC
or DE loop were altered. Type-specific MAbs (DENV1-E95,
DENV1-E101, DENV1-E104, DENV1-E108, DENV1-E111, and
DENV1-E112) that inhibited genotype 2 (16007) yet poorly
neutralized the genotype 4 (West Pac-74) strain mapped to
additional sites in DIII. DENV1-E95, DENV1-E104, DENV1E108, and DENV1-E112 exhibited reduced binding with
mutations in the G-strand (S390, W391, and K393) (Fig 3E)
whereas DENV1-E101 was affected by changes in the N-terminal
linker (T303) and BC-loop (G328, T329, and D330). Surprisingly,
none of the mutations altered DENV-E111 binding, and forward
genetic screens with this MAb also failed to identify a loss-ofbinding variant (data not shown). DENV1-E104, which showed
the weakest neutralizing activity, localized to residues in the A
(K310 and E311), F (E375), and G (S390 and W391) b-strands.
Because of analogous studies with DENV-2, we anticipated that
sub-complex-specific and cross-reactive MAbs would recognize the
A-strand epitope [25–27]. Indeed, mutation of S305, K307, E309,
K310, and E311 reduced binding of several sub-complex MAbs
(DENV1-E98, DENV1-E99, DENV1-E106, and DENV1-E113)
in our panel. For the cross-reactive neutralizing MAb DENV1E102, its epitope localized to residues in the N-terminal linker
region (Y299, V300, and M301) and the BC loop (D330 and P332)
(Fig 3F). Although Y299, M301, and P332 are highly conserved
among strains of different DENV serotypes, V300 is specific for
DENV-1 and D330 is present in DENV-1 and DENV-3; this may
explain why DENV1-E102 fails to neutralize DENV-2 and
DENV-3 efficiently (S. Sukupolvi-Petty, J. Brien, and M.
Diamond, unpublished results).
Despite the extensive epitope mapping data (summarized in
Fig 3B and 4), no structural explanation was readily apparent for
the decrease in neutralization of the genotype 4 West Pac-74 strain
by several antibodies. MAbs that showed markedly depressed
neutralization of West Pac-74 localized to residues that were
instead conserved among DENV-1 genotypes. To begin to address
this, we evaluated whether individual MAbs differentially
recognized DIII from 16007 or West Pac-74 strains when
expressed on yeast; the DIII of these two strain differ by only
two amino acids at positions 339 and 345 in the C strand and CC9 loop (Fig 3B). Notably, all neutralizing MAbs equivalently
recognized yeast displaying DIII of 16007 or West Pac-74 over a
range of concentrations (Fig 5A, and data not shown). Thus,
sequences differences in DIII of West Pac-74 and 16007 did not
explain the differential patterns of neutralization. Because of this,
we hypothesized that sequences variation in other domains of the
West Pac-74 E protein could directly alter MAb binding or
perhaps influence the display of DIII on the infectious virion. To
test this, we performed a virion capture ELISA with 16007 and
West Pac-74 viruses and selected MAbs having different
neutralization profiles against the two strains (Fig 5B). DENV1E98, which exhibited a ,50-fold reduction in neutralization
showed little difference in binding over several concentrations of
antibody. In contrast, DENV1-E111, which had ,4,000-fold less
neutralizing activity, exhibited a depressed ability to bind West
Pac-74 compared to 16007. Surprisingly, DENV1-E90 and
DENV1-E113, which had ,600 to 9,600-fold differences in
PRNT50 values with West Pac-74 compared to 16007 showed
virtually no variation in binding in the capture ELISA. Thus,
differential neutralization of genotypes 2 and 4 of DENV-1 could

Figure 2. Crystal structure of DENV-1 DIII (strain 16007) and
analysis of genotypic variation. Ribbon diagram of Ig-like fold of
DENV-1 DIII with b-strands and loops labeled accordingly after solution
of the X-ray crystallographic structure at 2.25 Å resolution. Amino acid
sequences in DIII that vary among the five different DENV-1 genotypes
are indicated, with solvent inaccessible and accessible residues
depicted in blue and green, respectively.
doi:10.1371/journal.ppat.1000823.g002

(16007) strain, and displayed these variants on the surface of yeast.
All DIII-specific MAbs were screened for loss-of-binding to the
mutants to identify potentially critical recognition residues. Using
this strategy, we localized binding of seven MAbs (DENV1-E100,
DENV1-E101, DENV1-E102, DENV1-E103, DENV1-E104,
DENV1-E105, and DENV1-E106) to individual or combinations
of amino acids on the BC, DE, and FG loops of the lateral ridge of
DIII (Table 5, Fig 3A, B, and C). Analogously, five MAbs
(DENV1-E99, DENV1-E100, DENV1-E104, DENV1-E106, and
DENV1-E113) exhibited reduced binding after mutation of Astrand (K307, E309, K310, and/or E311) residues (Fig 3D).
Three of the neutralizing MAbs (DENV1-E95, DENV1-E111,
and DENV1-E112), however, showed no appreciable reduction in
binding with analogous mutations in the lateral ridge or A-strand
residues that were identified from DENV-2 yeast screens.
Forward genetic screens subsequently were performed to define
additional residues that affected MAb binding. Error-prone PCR
introduced random point mutations within DIII of DENV-1 E
protein. Yeast were incubated sequentially with an Alexa Fluor 647conjugated individual MAb and an Alexa Fluor 488-conjugated
oligoclonal pool of MAbs to eliminate mutants that abolished
surface expression of DIII (see Materials and Methods). Yeast that
selectively lost expression of individual MAb epitopes were
identified, subjected to plasmid recovery, sequenced, and tested
for reactivity by flow cytometry against the remainder of the MAb
panel (Table 5). In total, 21 DIII residues were identified that when
changed resulted in a decrease in yeast staining by one or more
MAbs, with mutations in BC-loop residues most frequently
observed (Fig 3B). Only one of these residues (K/R361) is variable
amongst the five genotypes, an unexpected observation based on the
distinct genotypic specificities of the different MAbs.
PLoS Pathogens | www.plospathogens.org

6

April 2010 | Volume 6 | Issue 4 | e1000823

Therapeutic MAb Neutralization of DENV-1

Figure 3. Epitope localization of anti-DENV-1 MAbs. A. Flow cytometry histograms of loss-of-function DIII variants (V324I, T329G, D330G,
K361E, E362K, and E384K) with individual neutralizing MAbs. Representative histograms are shown for the MAbs WNV E16 (negative control), DENV1E95, DENV1-101, DENV1-103, and DENV1-106 with the wild type DIII and each of the variants. Data shown are representative of three independent
experiments. B. Sequence alignment of different DENV-1 genotypes and mapping of neutralizing MAbs. The sequence and secondary structure of DIII
from DENV-1 (strain 16007, genotype 2) E protein is aligned with other DENV-1 genotypes (genotype 1, strain TVP-2130; genotype 3, strain TVP 5175;
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genotype 4, strain Western Pacific-74; genotype 5, strain 3146 Sri Lanka). The secondary structure of DENV-1 E DIII residues 294 to 395 from the strains
that had not been crystallized was predicted by DSSP [112] using the 16007 strain coordinates. Black blocks highlight residues of genotypic variation.
The results of the yeast surface-display epitope mapping (see Table 5) are denoted underneath in red to indicate the number of neutralizing MAbs in
our panel that lose binding when a specific amino acid is changed. Colored boxes correspond to specific neutralizing antibody and structural recognition
determinants: N-terminal region, light purple; lateral ridge (BC, DE, and FG loops), dark purple; A-strand, cyan; and F- and G-strand, green. C–F.
Localization of neutralizing epitopes on DENV-1 DIII as determined by yeast surface display. Structure of DENV-1 DIII (strain 16007) with amino acid
residues marked in blue that significantly affect binding of neutralizing MAbs (C) DENV1-E106, (D) DENV1-E99, (E) DENV1-E95, and (F) DENV1-E102.
doi:10.1371/journal.ppat.1000823.g003

neutralizing antibodies against infection by the heterologous
strain, DENV-1 West Pac-74.

be explained by disparate binding to the virion for only a subset of
MAbs. For MAbs like DENV1-E90 and DENV1-E113, the profile
was similar to that observed with escape variants of a human antiWNV MAb; in that case, mutations that abolished neutralizing
activity did not appear to affect antibody binding to virus [48].

Therapeutic studies with neutralizing MAbs
Antibody-based therapeutics against DENV will need to be
administered after infection. To assess the therapeutic efficacy of
strongly neutralizing anti-DENV-1 MAbs, mice were infected with
106 PFU of West Pac-74 and two days after infection, a single
500 mg MAb dose (DENV1-E99, DENV1-E103, DENV1-E105,
or DENV1-E106) was transferred passively by an IP route.
Notably, 500 mg of DENV1-E99 or DENV1-E103 provided no
protection with animals dying at a rate and time similar to
untreated mice (P.0.2). In contrast, DENV1-E105 and DENV1E106 protected 75 and 82% (P#0.0001) of mice, respectively,
when administered two days after infection. When a single dose of
DENV1-E105 or DENV1-E106 MAb was given four days after
infection, 20 and 40% (P#0.03) of mice, respectively were
protected from lethal infection (Fig 7A and B).
Given the potency of DENV1-E105 and DENV1-E106 in
protection against the genotype 4 West Pac-74 strain, we performed PRNT50 analysis with strains corresponding to the
remaining genotypes to assess potential clinical utility of these
MAbs. Both DENV1-E105 and DENV1-E106 strongly neutralized infection of all DENV-1 genotypes (Fig 8A and B), with
PRNT50 values ranging from 0.5 to 59.2 ng/ml. Thus, DENV1E105 and DENV1-E106 protected AG129 immunocompromised
mice as a pre and post-exposure treatment from infection by a
heterologous DENV-1 genotype and efficiently inhibited all
DENV-1 genotypes in cell culture.

In vivo protection studies with neutralizing MAbs
Pre-exposure passive transfer of neutralizing MAbs against
WNV, DENV-2, and DENV-4 protects against lethal infection in
wild type and immunodeficient mice [24,29,52–56]. To confirm
that neutralizing anti-DENV-1 MAbs protect in vivo and begin to
explore the possibility for antibody therapy, we evaluated the
efficacy of our panel of inhibitory MAbs against West Pac-74, the
heterologous genotype 4 DENV-1 strain. The heterologous strain
was selected for two reasons: (i) the West Pac-74 strain was the
only DENV-1 isolate in our collection that caused 100% lethality
in an intraperitoneal challenge model in AG129 mice; and (ii) a
possible antibody therapeutic must demonstrate efficacy against
DENV-1 strains of different genotypes.
A single dose (500 mg) of neutralizing MAbs against DENV-1
was administered as prophylaxis one day prior to infection with
106 PFU of West Pac-74. Two MAbs (DENV1-E105 and
DENV1-E106) protected 100% of mice compared to PBS or
irrelevant MAb controls (P,0.0001), which had a 0% survival rate
(Table 6). Three other MAbs (DENV1-E99, DENV1-E100, and
DENV1-E103) exhibited strong yet incomplete protection with 60
to 80% survival rates. However, nine neutralizing MAbs (DENV1E90, DENV1-E95, DENV1-E98, DENV1-E101, DENV1-E102,
DENV1-E108, DENV1-E111, DENV1-E112 and DENV1-E113)
protected inefficiently, with an 11 to 38% survival rate. Although
the survival rate was relatively low for these MAbs, the mean time
to death (MTD) was protracted (2366.1 to 4068.6 days)
compared to untreated, infected mice (2063.3 days). One
neutralizing MAb, DENV1-E104 showed no protection against
lethality although a longer MTD was observed. In general, the
protective efficacy in vivo correlated with neutralizing activity
against the West Pac-74 genotype 4 strain. As an example,
DENV1-E105 and DENV1-E106 had low PRNT50 values (13 to
20 ng/ml) for West Pac-74 and protected against infection
whereas DENV1-E104 and DENV1-E112, which protected
poorly, had PRNT50 values (18 to 23 mg/ml) that were almost
1,000-fold different.
To begin to define the therapeutic potential of the highly
protective MAbs (DENV1-E99, DENV1-E103, DENV1-E105,
and DENV1-E106), we administered 5 and 25-fold lower doses
(100 mg and 20 mg) one day prior to IP infection of AG129 mice
with 106 PFU of West Pac-74. The lower doses of DENV1-E99
and DENV1-E103 provided sub-optimal protection against lethal
infection (Fig 6A and B), with only a delay in the MTD observed.
In comparison, ,50% of mice survived West Pac-74 infection
after receiving a single dose of 20 or 100 mg of DENV1-E105
antibody (Fig 6C, P#0.003). More strikingly, a single 20 or
100 mg injection of DENV1-E106 completely protected DENV-1
infected mice (Fig. 6D, P,0.0001). These data suggest that
DENV1-E106 was the most protective MAb in our panel of
PLoS Pathogens | www.plospathogens.org

Discussion
One primary goal of this study was to generate a collection of
strongly neutralizing MAbs that would recognize virtually all
DENV-1 strains and protect against infection as post-exposure
therapy. In an attempt to achieve this, we generated a panel of 79
new MAbs against DENV-1 E protein. Although neutralizing
antibodies can be generated against all three domains of the
flavivirus E protein [29,32,42,46,52,55,57,58], we mapped the
epitopes of the MAbs with the greatest inhibitory activity primarily
to epitopes on DIII, analogous to that observed with MAbs against
DENV-2 [25–27,41]. One surprising finding that has not been
reported previously was the disparate neutralizing activity and
protective potential of individual MAbs against different DENV-1
genotypes. In comparative studies with strains from genotype 2
and genotype 4, virtually all MAbs showed reduced (from 6 to
9,600-fold) PRNT50 values against the heterologous genotype.
Because of this, few (5 of 15) MAbs protected as pre-exposure
prophylaxis against infection by the heterologous DENV-1
genotype in AG129 mice, and only two (DENV1-E105 and
DENV1-E106) showed utility as post-exposure therapy.
Although many DENV strains can cause a similar debilitating
febrile illness in humans, there is significant genetic variation (25 to
40% amino acid difference for serotypes and up to 3% variation
among genotypes within a serotype) and phenotypic difference
in virulence among individual strains of specific serotypes and
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Table 5. Summary of MAb binding to DENV-1 DIII mutants expressed on the surface of yeast.
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AG129 mice. In contrast, three other neutralizing MAbs (DENV1E99, DENV1-E100, and DENV1-103) failed to protect when
added a few days after infection even though they functioned as
pre-exposure prophylaxis. Although prior studies demonstrated
that anti-E MAbs protect against DENV infection in rodents and
non-human primates [42,55,56,70,71], none have reported
efficacy when added after infection. It is noteworthy that the
two MAbs with the most neutralizing PRNT50 values were the
ones with greatest therapeutic efficacy, suggesting, at least for
strongly neutralizing MAbs of a given class, a correlation between
in vitro and in vivo activity. It is unclear why therapeutic antiDENV MAbs have not been previously described. Several postexposure therapeutic MAbs or polyclonal antibody preparations
against WNV, JEV, YFV, and tick-borne encephalitis virus have
been reported [29,30,53,57,72–77], with some entering human
clinical trials [43]. One speculation is that because viremia
associated with DENV infection is several log greater than WNV
[78–80], a condition of viral antigen excess occurs more rapidly in
circulation leading to fewer antibody molecules binding to a given
DENV virion. As neutralization is determined in part by the
stoichiometry of antibody binding [81,82], only MAbs that can
block infection at low fractional occupancy may be capable of
neutralizing in vivo.
MAb-based therapeutics against DENV could be complicated
by antibody-dependent enhancement of infection (ADE). Subneutralizing concentrations of antibody augment infection of Fc-c
receptor-expressing cells possibly by enhancing the efficiency of
virus attachment or entry [83,84]. Thus, the administration of
virus-specific MAbs could adversely impact the outcome of DENV
infection. In non-human primates, passive transfer of subneutralizing concentrations of monoclonal or polyclonal antibody
increased viremia although no change in disease status was
observed [85,86]. Based on the possibility of ADE, MAb
therapeutics against DENV in humans would appear to have
considerable regulatory hurdles. However, recent studies with
amino acid substitutions or deletions in the Fc region of
recombinant anti-flavivirus antibodies prevented ADE in vitro
and in vivo [86–88]. As such, studies are underway to engineer
mutations into the Fc region of a humanized version of DENV1E106 that abolishes the possibility of enhancement by abrogating
binding to Fc-c receptors.
Amino acid contact residues of neutralizing MAbs that react
with DENV-2 or DENV-3 have been defined by analyzing
neutralization escape mutants [40], chimeric DENV variants [89],
site-specific DENV-2 mutants [68,90], peptide mapping
[65,91,92], yeast surface display of variant E proteins [25,26,66],
mutant recombinant proteins [27,41,67], and by co-crystallography of recombinant DENV proteins and Fab fragments of
neutralizing MAbs [25]. Here, we used genetic strategies to
generate mutant DIII of DENV-1 on yeast to map antibody
recognition residues. The validity of the yeast surface display
mapping for identifying critical contact residues has been
confirmed by crystallographic studies that resolved the structural
interface between WNV and DENV2 DIII Fab fragments [25,93]
as well as DII-fusion loop specific Fab recognition [94]. For
neutralizing type-specific DENV-2 MAbs that mapped to specific
amino acid residues in DIII, the majority localized to residues in
the BC and FG loops within the lateral ridge [26,41]. Our yeast
mapping experiments confirm that the lateral ridge and A-strand
on DIII are also recognized by strongly neutralizing anti-DENV-1
antibodies.
The detailed mapping of neutralizing anti-DENV-1 MAbs
identified two additional regions on DIII that comprised protective
epitope(s): (a) DENV1-E102 and DENV1-E113, which react with

Figure 4. Summary of neutralizing antibody and structural
recognition determinants on DENV-1 DIII. Data from yeast surface
display (Table 5) and sequence alignment (Fig 3B) were mapped onto
the crystal structure of DENV-1 DIII to visualize the composite epitopes
of different neutralizing MAbs. Recognition sites include N-terminal
region, light purple; lateral ridge (BC, DE, and FG loops), dark purple; Astrand, cyan; and F- and G-strand, green.
doi:10.1371/journal.ppat.1000823.g004

genotypes [59–63]. Previous studies identified the lateral ridge and
A-strand epitopes in DIII as targets of strongly neutralizing typespecific and sub-complex-specific neutralizing MAbs against
DENV-2 and DENV-3 [26,27,41,64–67] and the fusion loop in
DII as a recognition site for many cross-reactive neutralizing
DENV MAbs [58,68,69]. In comparison, the serotype-specific
5H2 neutralizing MAb against DENV-4 localized to the loop
between the G and H b-strand in DI [42]. Prior to our study, little
was known as to how neutralizing antibodies recognized DENV-1.
Although neutralizing anti-DENV-1 MAbs have been generated
[44,45], few were localized to specific amino acids or structural
domains. Two neutralizing IgM against DENV-1 were mapped by
neutralization escape selection to amino acids E279 and E293, at
the hinges between DI and DII or DI and DIII, respectively [46].
While our experiments establish that highly neutralizing antibodies
recognize determinants in DIII of DENV-1, we do not rule out the
existence of other epitopes in distinct regions. Rather, the panel of
MAbs that we obtained may be skewed by the immunization
protocol (boosting with recombinant DIII), primary screen, and
genetic background of the animals, which influences the B cell
repertoire. Indeed, for WNV we have recently identified strongly
neutralizing and fusion-blocking human MAbs that poorly
recognize recombinant forms of the E protein and map to the
DI-DII hinge and dimer contact regions [48].
This is the first study that describes a post-exposure therapeutic
effect of a MAb against any DENV strain in any animal model. In
particular, DENV1-E105 and DENV1-E106, which neutralized
all five DENV-1 genotypes showed efficacy when administered
two or four days after infection of highly immunocompromised
PLoS Pathogens | www.plospathogens.org
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Figure 5. Binding of MAbs to DIII or virions of 16007 and West Pac-74. A. MAb binding to DIII of 16007 or West Pac-74 on yeast. Flow
cytometry histograms of DIII of 16007 or West Pac-74 (different at residues 339 and 345) with neutralizing MAbs. Data shown are representative of
two independent experiments. B. A capture ELISA was used to detect binding of MAbs to 16007 and West Pac-74 virions. Microtiter plates were
coated with the indicated MAbs, incubated with 26105 PFU of 16007 or West Pac-74 at room temperature, and with biotinylated anti-E MAbs. The
data is an average of several separate experiments performed in duplicate, and error bars indicate standard deviation.
doi:10.1371/journal.ppat.1000823.g005
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Although our most strongly neutralizing MAbs localized to DIII
of DENV-1, these antibodies were derived from immunodeficient
mice, which may not necessarily reflect the neutralizing antibody
response in humans. The antibody repertoire against DENV-1 or
other serotypes in humans remains unknown, as B cell profiling at
the epitope level has not been performed. Nonetheless, recent
studies suggest that the humoral response against flaviviruses in
humans may be directed away from DIII neutralizing epitopes
[53,54,95]. DIII-specific antibodies comprised only a small
fraction of the total antibody in DENV immune sera [96,97];
whether these antibodies contribute to DENV neutralization in
vivo remains controversial. Because highly neutralizing antibodies
against DIII of DENV-1, DENV-2, and DENV-3 map to the
lateral ridge and A-strand epitopes [26,27,41,67], DIII-based
vaccines [98–101] that skew the humoral response have the
potential to elicit highly protective responses.
One intriguing finding was the disparate neutralizing activity of
individual MAbs against different DENV-1 genotypes. Infection
with one DENV serotype is believed to confer long-term immunity
against strains of the homologous but not heterologous DENV
serotypes. Based on this, we assumed it would be straightforward
to generate DIII-specific therapeutic MAbs that neutralized all five
genotypes within the DENV-1 serotype. Indeed, there are limited
amino acid changes in DIII among DENV-1 genotypes with a
maximum difference of seven amino acids, with genotype 5 the
most diverse although the changes are largely conserved and reside
in solvent inaccessible regions. Nonetheless, several MAbs in the
panel exhibited markedly depressed neutralizing activity against
the heterologous West Pac-74 strain. This was perplexing given
that the 16007 and West Pac-74 strains differ in DIII by two
amino acids, which were not coincident with our epitope mapping
data: a TRS change at residue 339 in the C-strand and an ARV
change at residue 345 in the C-C9 loop. Indeed, in comparative
binding assays with 16007 and West Pac-74 DIII on yeast, no
obvious difference in binding at saturating concentrations of MAb
was observed. When studies were repeated with selected MAbs in
a virus capture ELISA, one MAb (DENV1-E111) with disparate
neutralizing potential showed reduced binding to West Pac-74, but
others (DENV1-E90 and DENV1-E113) did not. This was
corroborated in surface plasmon resonance studies, which showed
an ,10-fold decrease in the KD of binding of DENV1-E111
for West Pac-74 DIII (K. Austin, M. Diamond, D. Fremont,
unpublished results). Although further structural studies are
warranted, we propose four hypotheses to explain these results:
(a) similar to findings with a recently characterized human antiWNV MAb [48], mutations that abrogate neutralizing activity do
not always reduce measurable antibody binding to the virion; (b)
because of sequence variation outside of DIII, the E protein of
different DENV-1 genotypes may pack differently on the virion.
Some components of an epitope for a given MAb may be
differentially exposed on virions of distinct genotype; (c) individual
loss-of-function mutations identified by yeast display do not
necessarily represent the complete footprint on DIII of bound
antibody, as mutation of other residues may have allosteric effects;
or (d) neutralizing anti-DENV-1 MAbs in our panel may have
additional amino acid contacts outside of DIII that vary among
the DENV-1 genotypes. Notably, we did not observe detectable
binding of any the DIII-specific neutralizing MAbs to a DI-DII
protein displayed on yeast (data not shown). Structural studies with
Fab-E protein or Fab-virion complexes will be required to address
these possibilities.
Regardless of the mechanism, our results suggest that antibodies
against one DENV genotype may have decreased inhibitory
potency against a heterologous genotype within the same serotype.

Table 6. In vivo protection of AG129 mice from West Pac-74
(genotype 4) after prophylaxis with neutralizing anti-DENV-1
MAbs.

MAb

Dose
(mg/mouse)

Survival

MTDa 6 SD
2063

P valueb

No MAb

0

0/12

WNV E16

500

0/5

1862

NS

DENV1-E90

500

2/9

3767

,0.0001

DENV1-E95

500

2/10

36611

,0.0001

DENV1-E98

500

2/8

34614

0.002

DENV1-E99

500

6/8

5263

,0.0001

DENV1-E100

500

6/10

35617

,0.0001

DENV1-E101

500

3/8

34612

0.0005

DENV1-E102

500

1/9

2366

0.03

DENV1-E103

500

7/10

29614

,0.0001

DENV1-E104

500

0/8

2668

0.03

DENV1-E105

500

8/8

NA

,0.0001

DENV1-E106

500

10/10

NA

,0.0001

DENV1-E108

500

2/8

4069

,0.0001
0.001

DENV1-E111

500

2/8

2868

DENV1-E112

500

1/8

25611

0.03

DENV1-E113

500

1/8

34611

0.001

Mice were administered with 500 mg of indicated MAbs one day before
infection with 106 PFU of West Pac-74 by an IP route. Mice were monitored for
survival for 60 days after infection. NS, not statistically different from PBS
control.
a
Mean time to death (MTD) 6 standard deviations (SD) refers to the mean time
to death of the animals that succumbed to fatal infection. NA, indicates that no
animals died in the presence of this MAb, and thus, the value was not
calculated.
b
P values were calculated using the log rank test of the Kaplan Meier survival
curve by comparing the no antibody treated and antibody treated mice.
doi:10.1371/journal.ppat.1000823.t006

multiple DENV serotypes, showed an almost complete loss-ofbinding with mutation of residues (Y299, V300, and M301) in the
N-terminal linker region. This result is analogous to that described
for neutralizing DENV-2 MAbs where the mutation M301G
abolished reactivity of five complex-specific and seven serotypespecific MAbs [27,41]. The binding of the N-terminal linker by
MAbs against WNV has been speculated to contribute to
neutralization by inhibiting the significant rotation of DIII during
the dimer to trimer transition [93]. (b) DENV1-E95, DENV1-E98,
DENV1-E104, DENV1-E108, and DENV1-E112 exhibited loss
of binding when residues (S390, W391, and K393) in the G-strand
were changed. As the G-strand of the DIII is solvent accessible on
the surface of the DENV virion [7], it is structurally feasible that
recognition of this region by MAbs will inhibit infection. Indeed, in
experiments that assessed the reactivity of a panel of complexspecific neutralizing MAbs against DENV-2 and DENV-3 DIII,
mutation of G-strand residues also reduced binding [27,67].
Additionally, X-ray crystallography studies identified residues
K388 and N390 in the G-strand of DENV-2 as contacts for the
neutralizing sub-complex-specific MAb 1A1D-2 [25]. These
studies suggest that DIII is a complex antigen that is recognized
by neutralizing MAbs that localize to one of four overlapping
regions: the N-terminal linker, A-strand, lateral ridge loops, and
G-strand. What remains uncertain is whether binding to specific
determinants on DIII influences the mechanism of antibody
neutralization of DENV.
PLoS Pathogens | www.plospathogens.org
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Figure 6. Dose response of protective efficacy MAbs in mice infected with DENV-1. AG129 mice were passively transferred saline or 20,
100, or 500 mg of (A) DENV1-E99, (B) DENV1-E103, (C) DENV1-E105, and (D) DENV1-E106 MAbs one day before infection with 106 PFU of West Pac-74
(genotype 4) by an IP route. Mice were monitored for survival for 60 days after infection. The survival curves were constructed from data of two
independent experiments. The number of animals for each antibody dose ranged from 5 to 10 per group.
doi:10.1371/journal.ppat.1000823.g006

This has potential implications for assessing the breadth
of the protective efficacy of tetravalent DENV vaccines, which
are in advanced clinical trials. In addition to evaluating
protection against other serotypes, it may be critical to assess
whether antibody responses against the vaccine strain of a
given serotype neutralize infection of heterologous genotypes
equivalently.

Materials and Methods
Cells and viruses
Vero, BHK21-15 and Raji-DC-SIGN-R cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) (Omega Scientific) and antibiotics
(penicillin G and streptomycin) at 37uC in a 5% CO2 incubator.

Figure 7. Therapeutic efficacy of strongly neutralizing antibodies in mice after DENV-1 infection. Mice were administered saline or a
single 500 mg dose of DENV1-E105 or DENV1-E106 MAbs at day (A) 2 or (B) 4 after infection with 106 PFU of West Pac-74 (genotype 4) by an IP route.
Mice were monitored for survival for 60 days after infection. The number of animals for each antibody ranged from 10 to 11 per group.
doi:10.1371/journal.ppat.1000823.g007
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(Invitrogen). For library sorting experiments, MAbs were labeled
with Alexa Fluor 647 or Alexa Fluor 488, using a MAb labeling kit
(Molecular Probes) according to the manufacturer’s instructions.

In vitro neutralization assay
Plaque reduction neutralization titer (PRNT) assays were
performed with the indicated DENV-1 strains with MAbs or
serum on BHK21-15 cells as described previously [26,80].
PRNT50 values were determined using non-linear regression
analysis (Graph Pad Prism4).

Cloning and expression of DIII of DENV-1 E protein
A cDNA encoding DENV-1 DIII (strain 16007, residues 293 to
400) of the 16007 strain was amplified from viral RNA by reverse
transcriptase and high-fidelity Platinum Taq polymerase chain
reaction (PCR) according to the manufacturer’s instructions
(Invitrogen). The PCR product was cloned into the pET21a
bacterial expression plasmid (EMD Biosciences) using flanking
NdeI and XhoI restriction sites, sequenced, and then expressed in
BL21 Codon Plus (Stratagene) E. coli. Inclusion bodies containing
insoluble aggregates were denatured in the presence of 6 M
guanidine hydrochloride and 20 mM b-mercaptoethanol and
refolded in the presence of 400 mM L-arginine, 100 mM Trisbase (pH 8.0), 2 mM EDTA, 0.2 mM phenylmethylsulfonyl
fluoride, and 5 and 0.5 mM reduced and oxidized glutathione,
respectively. Refolded protein was separated from aggregates on a
Superdex 75 or 200, 16/60 size exclusion column using fastprotein liquid chromatography (GE Healthcare).

Figure 8. PRNT50 analysis of different DENV-1 genotypes by
DENV1-E105 and DENV1-E106. Increasing concentrations of
purified (A) DENV1-E106 and (B) DENV1-E105 were mixed with 102
PFU of DENV-1 strains corresponding to all five genotypes and
neutralization was assessed by a standard PRNT assay in BHK or Vero
cells (depending on the strain). PRNT50 values were calculated after
regression analysis using statistical software. The graph is representatives of at least two independent experiments performed in duplicate.
doi:10.1371/journal.ppat.1000823.g008

X-ray crystallographic structure determination of DV1 DIII
DENV-1 DIII was crystallized by vapor diffusion in hanging
drops at 20uC at a concentration of 14 mg/ml. The drop
contained equal parts protein and well solution composed of
0.1 M imidazole-HCl at pH 7.5, 0.2 M lithium sulfate, and 30%
(w/v) polyethylene glycol 3000. Crystals were cryoprotected after a
soak in well solution containing 15% glycerol before rapid cooling
in a nitrogen gas stream. Data was collected at ALS beamline 4.2.2
(Lawrence Berkeley Laboratories, Berkeley, CA) at 293u K and at
a wavelength of 1.29 Å using a CCD detector. The data were
processed and scaled in HKL-3000 [103]. Crystallographic
phasing was obtained by molecular replacement using the
program Phaser [104] and the corresponding DIII fragment from
DV2 (PDB accession 1OAN) as a search model. The resulting
atomic model was iteratively built in O [105] and refined in
REFMAC [106]. The final model with one DENV1 DIII
monomer per asymmetric unit has been refined to 2.25Å
resolution and contains 103 amino acids (residues 296 to 399 of
DIII) and 53 water molecules. The DENV1 DIII domain is similar
in structure to that reported for the post-fusion DENV-1 E
ectodomain trimer (3G7T) [11] with a root-mean-square difference of 1.6 Å between Ca atom positions for equivalent core
residues 296 through 394 [107]. The coordinates and diffraction
data have been deposited in the RCSB with accession number
3IRC.

Strains from all five genotypes of DENV-1 included: TVP-2130
(genotype 1), 16007 (genotype 2), TVP-5175 (genotype 3), Western
Pacific-74 (genotype 4) and 3146 Sri Lanka (genotype 5). TVP2130 and TVP-5175 were obtained from Dr. Robert Tesh and the
World Reference Center for Emerging Viruses and Arboviruses
(University of Texas Medical Branch, Galveston, TX). Western
Pacific-74 (West Pac-74) and the 3146 Sri Lanka strain were
obtained from Drs. Stephen Whitehead (NIAID, NIH, Bethesda,
MD) and Rebeca Rico-Hesse (Southwest Foundation for Biomedical Research, San Antonio, Texas), respectively. Strains corresponding to other DENV serotypes were also used: 16681 (DENV2), 16652 (DENV-3), and H241 (DENV-4). All viruses were
amplified in C6/36 Aedes albopictus cells according to previously
described protocols [26].

Generation, purification, and labeling of anti-DENV-1
MAbs
MAbs were generated essentially as described [29] after
performing several independent splenocyte-myeloma fusions. To
generate anti-DENV-1 MAbs, IFN-abR2/2 C57BL/6 mice were
infected with 105 PFU of DENV-1 strain 16007 (genotype 2) via
an intraperitoneal route and re-challenged two weeks later with
the same strain. Mice with serum having the highest neutralizing
titer (.1/1500) were immunized with purified DIII (50 mg, strain
16007) in PBS as a final intravenous boost. Three days later
splenocytes were fused to P3X63Ag8.53 myeloma cells [102].
MAbs were subcloned by limiting dilution, isotyped (Pierce Rapid
ELISA Kit), and purified using protein A affinity chromatography
PLoS Pathogens | www.plospathogens.org

Domain mapping by yeast surface display
The DNA fragments encoding amino acid residues 1 to 293
(DI-DII) and 294 to 409 (DIII) of DENV-1 E protein were
amplified from the DENV-1 strain 16007 or West Pac-74 by RTPCR with BamHI and XhoI sites added at the 59 and 39 end,
respectively. The PCR products were cloned as downstream
fusions to Aga2 and Xpress epitope tag genes in the yeast surface
display vector pYD1 (Invitrogen), under the control of an
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upstream GAL1 promoter. These constructs were transformed
into Saccharomyces cerevisiae strain EBY100 [108,109] using S.c.
EasyComp Transformation Kit (Invitrogen) to generate yeast that
expressed DENV-1 DI-DII or DIII. Individual yeast colonies were
grown to logarithmic phase at 30uC in tryptophan-free yeast
media containing 2% glucose. Fusion protein expression was
induced on the surface by growing yeast for additional 48 hrs in
tryptophan-free media containing 2% galactose at 20uC. Yeast
cells were washed with PBS supplemented with BSA (1 mg/ml)
and incubated with 50 ml of neat culture supernatant or purified
MAbs at a concentration of 25 mg/ml. After a 30 minute
incubation on ice, yeast were washed in PBS with BSA and then
incubated with a goat anti-mouse IgG secondary antibody
conjugated to Alexa Fluor 647 (Molecular Probes). After fixation
with 1% paraformaldehyde in PBS, yeast cells were analyzed on a
FACSArray flow cytometer (Becton-Dickinson) using FloJo
software.

flaviviruses, infection and staining experiments were performed
with WNV (strain 3000.0259) and Raji-DC-SIGN-R cells as
described previously [52].

DENV-1 virus capture ELISA
The capture ELISA for DENV-1 was based on a published
assay for WNV with modifications [48]. Briefly, anti-DENV-1
MAbs were coated at indicated concentrations on MaxiSorp
(Nunc) polystyrene 96-well microtiter plates in a sodium carbonate
(pH 9.3) buffer. Plates were washed three times in ELISA wash
buffer (PBS with 0.02% Tween 20) and blocked for 1 hour at
37uC with ELISA block buffer (PBS, 2% bovine serum albumin,
and 0.02% Tween 20). DENV-1 virions (2.5 to 5.06105 PFU of
strain 16007 or West Pac-74) diluted in DMEM with 10% heatinactivated FBS were captured on plates coated with anti-DENV1 MAbs for 2 hours at room temperature. Plates were rinsed five
times in wash buffer and then incubated with biotinylated 4G2
(1 mg/ml, respectively diluted in ELISA block buffer), which
recognizes the fusion loop peptide in DII, for 1 hour at room
temperature. Plates were washed again five times and then
sequentially incubated with 2 mg/ml of horseradish peroxidaseconjugated streptavidin (Vector Laboratories) and tetramethylbenzidine substrate (Dako). The reaction was stopped with the
addition of 2 N H2SO4 to the medium, and emission (450 nm) was
read using an iMark microplate reader (Bio-Rad).

Yeast library construction and screening
To generate a library of DENV-1 DIII variants on yeast,
mutation was accomplished by error-prone PCR, using a
GeneMorph II random mutagenesis kit (Stratagene). The library
was ligated into the pYD1 vector and transformed into XL2-Blue
ultracompetent cells (Stratagene). The colonies were pooled and
transformed into yeast cells as described above. In some instances,
additional site-specific mutations were engineered into DENV-1
DIII by a reverse genetic approach using the Quick Change II
Mutagenesis Kit (Stratagene).
For individual MAbs, the DENV-1 DIII mutant library was
screened according to a previously described protocol [29]. To
identify yeast that had selectively lost binding to a given MAb, the
library was stained with an individual Alexa Fluor 647 conjugated
MAb for 30 min on ice. To control for surface expression of
appropriately folded DIII of DENV-1, yeast cells were subsequently stained for 30 min on ice with an Alexa Fluor 488conjugated pool of DIII-specific MAbs (DENV1-E90, DENV1E95, DENV1-E99, DENV1- DENV1-E111, DENV1-E112, and
DENV1-E113), and then processed by flow cytometry, The
population that was single MAb negative but pool oligoclonal
MAb positive was selected and sorted. After four to five rounds of
sorting, yeast were plated and individual colonies were tested for
binding to individual MAbs by flow cytometry. For clones that had
lost binding to the desired MAb of interest, the plasmid was
recovered using a Zymoprep yeast miniprep kit (Zymo Research),
transformed into XL1-Blue competent E. Coli (Stratagene),
purified using a QIAprep spin miniprep kit (Qiagen), and
sequenced.

Mouse experiments
All mouse studies were approved and performed according to
the guidelines of the Washington University School of Medicine
Animal Safety Committee. IFN-abR2/2 6 cR2/2 mice on the
129 Sv background (AG129 mice) were a gift from Dr. Skip Virgin
(Washington University School of Medicine) and bred in a
pathogen-free barrier facility. In prophylaxis experiments, AG129
mice were administered a single dose of individual MAbs one day
before infection. Subsequently, mice were challenged with West
Pac-74 (genotype 4, 106 PFU) by an IP route and morbidity and
mortality were monitored for 60 days. In post-exposure therapeutic experiments, a single 500 mg dose of MAb dose was
administered by IP injection two or four days after infection with
106 PFU of West Pac-74.

Mapping of mutations onto the DENV-1 DIII crystal
structure
Figures were prepared using the atomic coordinates of DENV-1
DIII (RCSB accession number 3IRC) using the programs
CCP4MG [110]. The alignment of DENV-1 DIII from different
genotypes was created with the program ALSCRIPT [111].

Immunostaining of DENV-infected cells
For the study of binding of DENV-1 MAbs to different DENV
strains, Raji-DC-SIGN-R or C6/36 cells were infected with
different DENV strains at a multiplicity of infection (MOI)
of 1. Depending on the DENV-1 strain, Raji-DC-SIGN-R cells
were harvested at 48 or 96 hours and C6/36 cells were
harvested at day 7 after infection. Cells were washed, fixed in
PBS with 4% paraformaldehyde, and permeabilized in Hanks’
balanced salt solution (HBSS) supplemented with 10 mM
HEPES (pH 7.3), 0.1% (w/v) saponin (Sigma), and 0.02%
NaN3. The cells were then incubated with MAbs for 30 minutes
on ice, washed and incubated subsequently with an Alexa Fluor
647-conjugated goat anti-mouse IgG (Molecular Probes). After
30 minutes, cells were washed and fixed in PBS with 1%
paraformaldehyde and analyzed by flow cytometry. To test
whether DENV-1 MAbs cross-reacted with more distantly related
PLoS Pathogens | www.plospathogens.org

Statistical analysis
All data were analyzed using Prism software (GraphPad
software). For survival analysis, Kaplan-Meier survival curves
were analyzed by log-rank test. For neutralization assays an
unpaired student’s T-test was used to determine significance.

Supporting Information
Table S1 Profile of DENV-1 MAbs
Found at: doi:10.1371/journal.ppat.1000823.s001 (0.06 MB
DOC)
Table S2 Summary of Data Collection and Refinement
Found at: doi:10.1371/journal.ppat.1000823.s002 (0.03 MB
DOC)
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